These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15692103)

  • 21. Synergism between tissue-type plasminogen activator and a genetically engineered variant lacking the finger domain, the growth factor domain and the first kringle domain.
    Mattson C; Wikström K; Sterky C; Pohl G
    Thromb Haemost; 1991 Mar; 65(3):286-90. PubMed ID: 1710837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression and characterization of Kringle 1-4.5 domains of human plasminogen].
    Zhou QW; Xie JL; Xin L; Xu R; Ye Q; Li ZP; Gan RB
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Feb; 35(2):138-42. PubMed ID: 12545220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer.
    Matsuda KM; Madoiwa S; Hasumi Y; Kanazawa T; Saga Y; Kume A; Mano H; Ozawa K; Matsuda M
    Cancer Gene Ther; 2000 Apr; 7(4):589-96. PubMed ID: 10811477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
    Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
    Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth.
    Cao Y; Chen A; An SS; Ji RW; Davidson D; Llinás M
    J Biol Chem; 1997 Sep; 272(36):22924-8. PubMed ID: 9278456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
    Rydzewski A; Castellino FJ
    Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen).
    Goretzki L; Lombardo CR; Stallcup WB
    J Biol Chem; 2000 Sep; 275(37):28625-33. PubMed ID: 10889192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent anti-tumor and prolonged survival effects of E. coli-derived non-glycosylated kringle domain of tissue-type plasminogen activator.
    Kang BH; Shim BS; Lee SY; Lee SK; Hong YK; Joe YA
    Int J Oncol; 2006 Feb; 28(2):361-7. PubMed ID: 16391790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.
    Zhang D; Kaufman PL; Gao G; Saunders RA; Ma JX
    Diabetologia; 2001 Jun; 44(6):757-65. PubMed ID: 11440369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A kringle-containing protease with plasminogen-like activity in the basal chordate Branchiostoma belcheri.
    Liu M; Zhang S
    Biosci Rep; 2009 Sep; 29(6):385-95. PubMed ID: 19193194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
    Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
    Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production and characterization of a novel tissue-type plasminogen activator derivative in Escherichia coli.
    Saito Y; Ishii Y; Sasaki H; Hayashi M; Fujimura T; Imai Y; Nakamura S; Suzuki S; Notani J; Asada T
    Biotechnol Prog; 1994; 10(5):472-9. PubMed ID: 7765373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-level secretion in Pichia pastoris and biochemical characterization of the recombinant kringle 2 domain of tissue-type plasminogen activator.
    Nilsen SL; DeFord ME; Prorok M; Chibber BA; Bretthauer RK; Castellino FJ
    Biotechnol Appl Biochem; 1997 Feb; 25(1):63-74. PubMed ID: 9032937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis.
    Xin L; Xu R; Zhang Q; Li TP; Gan RB
    Biochem Biophys Res Commun; 2000 Oct; 277(1):186-90. PubMed ID: 11027661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different evolutionary histories of kringle and protease domains in serine proteases: a typical example of domain evolution.
    Ikeo K; Takahashi K; Gojobori T
    J Mol Evol; 1995 Mar; 40(3):331-6. PubMed ID: 7723060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli.
    Manosroi J; Tayapiwatana C; Götz F; Werner RG; Manosroi A
    Appl Environ Microbiol; 2001 Jun; 67(6):2657-64. PubMed ID: 11375177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.